EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Characterization of a novel heterozygous variant in the histidyl‐ tRNA synthetase gene associated with Charcot–Marie–Tooth disease type 2W

Sarah D P Wilhelm, Angelica A Moresco, Alberto D Rivero, Victoria Mok Siu, Ilka U Heinemann iD

IUBMB Life · 2024

DOI: 10.1002/iub.2918 ↗

Kurz gefasst

Fallbericht in der Zeitschrift IUBMB Life, 2024. Verfasst von Sarah D P Wilhelm und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, The University of Western Ontario, London, Ontario, Canada. Hauptthemen laut MEDLINE: Charcot-Marie-Tooth Disease, Heterozygote, Histidine-tRNA Ligase. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Rare Disease Models and Mechanism Network, Ontario Ministry of Research and Innovation, Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heterozygous pathogenic variants in the histidyl‐tRNA synthetase ( HARS ) gene are associated with Charcot–Marie–Tooth (CMT) type 2W disease, classified as an axonal peripheral neuropathy. To date, at least 60 variants causing CMT symptoms have been identified in seven different aminoacyl‐tRNA synthetases, with eight being found in the catalytic domain of HARS. The genetic data clearly show a causative role of aminoacyl‐tRNA synthetases in CMT; however, the cellular mechanisms leading to pathology can vary widely and are unknown in the case of most identified variants. Here we describe a novel HARS variant, c.412T>C; p.Y138H, identified through a CMT gene panel in a patient with peripheral neuropathy. To determine the effect of p.Y138H we employed a humanized HARS yeast model and recombinant protein biochemistry, which identified a deficiency in protein dimerization and a growth defect which shows mild but significant improvement with histidine supplementation. This raises the potential for a clinical trial of histidine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Charcot-Marie-Tooth DiseaseHeterozygoteHistidine-tRNA LigaseFemaleHumansMaleHistidineAdult

Stichwörter der Autor:innen

Charcot–Marie–Tooth diseasehistidinehistidyl‐tRNA synthetaseprotein synthesisvariant of uncertain significance

Substanzen

HistidineHistidine-tRNA Ligase

Autor:innen und Institutionen

  • Department of Biochemistry, The University of Western Ontario, London, Ontario, Canada.
  • Division of Medical Genetics, Department of Paediatrics, The University of Western Ontario, London, Ontario, Canada.
  • Institute for Neurological Research (FLENI), Buenos Aires, Argentina.
  • Children's Health Research Institute, London, Ontario, Canada.

ORCID-Profile: Ilka U Heinemann

Förderung

  • Rare Disease Models and Mechanism Network
  • Ontario Ministry of Research and Innovation
  • Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada
  • Institute of Genetics

Zitieren

APA

Wilhelm, S. D. P., Moresco, A. A., Rivero, A. D., Siu, V. M., & Heinemann, I. U. (2024). Characterization of a novel heterozygous variant in the histidyl‐ tRNA synthetase gene associated with Charcot–Marie–Tooth disease type 2W. IUBMB Life. https://doi.org/10.1002/iub.2918

Vancouver

Wilhelm SDP, Moresco AA, Rivero AD, Siu VM, Heinemann IU. Characterization of a novel heterozygous variant in the histidyl‐ tRNA synthetase gene associated with Charcot–Marie–Tooth disease type 2W. IUBMB Life. 2024. doi:10.1002/iub.2918

BibTeX
@article{Wilhelm2024,
  author = {Wilhelm, Sarah D P and Moresco, Angelica A and Rivero, Alberto D and Siu, Victoria Mok and Heinemann, Ilka U},
  title = {Characterization of a novel heterozygous variant in the histidyl‐ tRNA synthetase gene associated with Charcot–Marie–Tooth disease type 2W},
  journal = {IUBMB Life},
  year = {2024},
  doi = {10.1002/iub.2918}
}
Kostenlos starten →